Full Year 2018 Medicure Inc Earnings Call Transcript
Welcome to fiscal year-end 2018 conference call. My name is Sylvia, and I will be your operator for today's call. (Operator Instructions) Please note that this conference is being recorded. I will now turn the call over to Dr. Albert Friesen. Dr. Friesen, you may begin.
Thanks, Sylvia, and good morning to you all. We appreciate your interest and participation on today's call. Joining me on the call is our CFO, James Kinley; and our Vice President Commercial Operations, Kevin Taylor.
For the number of patients using AGGRASTAT, our main drug, continue to increase throughout 2018 to approximately 65% of the patient market by the end of 2018, up from the 63% reported in the third quarter of 2018. The revenue for the quarter ending December 31, 2018, from AGGRASTAT was $8.2 million, which is up from the $7 million revenue recorded Q3 2018. As expected, revenue from Medicure's second drug on the U.S. market, ZYPITAMAG, is still small, as we wait for the various insurance coverages
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
